Trials / Completed
CompletedNCT01563081
Safety Study of Levocetirizine Oral Solution for Japanese Pediatrics
A Multi-Center, Open-labelled Study to Evaluate the Safety of Levocetirizine Hydrochloride Oral Solution in Children Aged 6 Months to 2 Years With Allergic Rhinitis or Pruritus Associated With the Skin Diseases.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 6 Months – 23 Months
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety of treatment with levocetirizine oral solution in pediatric patients aged form 6 months to 2 years old with allergic rhinitis or pruritus associated with the skin diseases.
Detailed description
This is a multi-center, open-labelled study to confirm the safety as main objective, and consisting of minimum 1-week screening period and 2-week treatment period. The subjects who meet the inclusion criteria are to be placed on one of the following two regimens according to their ages at the start of treatment period: once daily administration of levocetirizine at a dose of 1.25 mg (in the morning) to infants aged between 6 months and 1 year old (younger age group), and twice daily administration of levocetirizine at a dose of 1.25 mg (in the morning, in the evening before sleep) to infants aged between 1 year and 2 years old (older age group).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levocetirizine | Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered once daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning to infants aged between 6 months and 1 year old |
| DRUG | Levocetirizine | Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered twice daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning and evening before sleep to infants aged between 1 year and 2 years old |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2012-08-01
- Completion
- 2012-08-01
- First posted
- 2012-03-26
- Last updated
- 2017-02-28
- Results posted
- 2013-06-03
Locations
7 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01563081. Inclusion in this directory is not an endorsement.